Cargando…
Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain
PURPOSE: The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed. METHODS: A questionnaire was sent to 146 hospitals in S...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578161/ https://www.ncbi.nlm.nih.gov/pubmed/32533318 http://dx.doi.org/10.1007/s12094-020-02366-y |
_version_ | 1783598306250719232 |
---|---|
author | Rodríguez-Lescure, A. de la Peña, F. A. Aranda, E. Calvo, A. Felip, E. Garrido, P. Vera, R. |
author_facet | Rodríguez-Lescure, A. de la Peña, F. A. Aranda, E. Calvo, A. Felip, E. Garrido, P. Vera, R. |
author_sort | Rodríguez-Lescure, A. |
collection | PubMed |
description | PURPOSE: The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed. METHODS: A questionnaire was sent to 146 hospitals in Spain to collect information on the process of approval of 11 oncology drugs of an unquestionable clinical benefit and five predictive biomarkers of mandatory determination for specific treatments. RESULTS: Results highlight the still existing differences in the access of oncology drugs, as well as the newly identified differences in the access to predictive biomarkers between Autonomous Communities (AACC) in Spain, as well as between different hospitals within the same Autonomous Community. Conclusions The SEOM considers it necessary to reduce the differences identified, increase homogeneity, and improve conditions of access to oncology drugs and biomarkers, and makes proposals to address these issues. |
format | Online Article Text |
id | pubmed-7578161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-75781612020-10-27 Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain Rodríguez-Lescure, A. de la Peña, F. A. Aranda, E. Calvo, A. Felip, E. Garrido, P. Vera, R. Clin Transl Oncol Research Article PURPOSE: The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed. METHODS: A questionnaire was sent to 146 hospitals in Spain to collect information on the process of approval of 11 oncology drugs of an unquestionable clinical benefit and five predictive biomarkers of mandatory determination for specific treatments. RESULTS: Results highlight the still existing differences in the access of oncology drugs, as well as the newly identified differences in the access to predictive biomarkers between Autonomous Communities (AACC) in Spain, as well as between different hospitals within the same Autonomous Community. Conclusions The SEOM considers it necessary to reduce the differences identified, increase homogeneity, and improve conditions of access to oncology drugs and biomarkers, and makes proposals to address these issues. Springer International Publishing 2020-06-12 2020 /pmc/articles/PMC7578161/ /pubmed/32533318 http://dx.doi.org/10.1007/s12094-020-02366-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Rodríguez-Lescure, A. de la Peña, F. A. Aranda, E. Calvo, A. Felip, E. Garrido, P. Vera, R. Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain |
title | Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain |
title_full | Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain |
title_fullStr | Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain |
title_full_unstemmed | Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain |
title_short | Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain |
title_sort | study of the spanish society of medical oncology (seom) on the access to oncology drugs and predictive biomarkers in spain |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578161/ https://www.ncbi.nlm.nih.gov/pubmed/32533318 http://dx.doi.org/10.1007/s12094-020-02366-y |
work_keys_str_mv | AT rodriguezlescurea studyofthespanishsocietyofmedicaloncologyseomontheaccesstooncologydrugsandpredictivebiomarkersinspain AT delapenafa studyofthespanishsocietyofmedicaloncologyseomontheaccesstooncologydrugsandpredictivebiomarkersinspain AT arandae studyofthespanishsocietyofmedicaloncologyseomontheaccesstooncologydrugsandpredictivebiomarkersinspain AT calvoa studyofthespanishsocietyofmedicaloncologyseomontheaccesstooncologydrugsandpredictivebiomarkersinspain AT felipe studyofthespanishsocietyofmedicaloncologyseomontheaccesstooncologydrugsandpredictivebiomarkersinspain AT garridop studyofthespanishsocietyofmedicaloncologyseomontheaccesstooncologydrugsandpredictivebiomarkersinspain AT verar studyofthespanishsocietyofmedicaloncologyseomontheaccesstooncologydrugsandpredictivebiomarkersinspain |